Geneoscopy Settles Legal Disputes and Focuses on Colorectal Health Advancements

Geneoscopy Resolves Legal Matters with Exact Sciences



Geneoscopy, Inc., a prominent player in the healthcare diagnostics landscape, has successfully settled its ongoing litigation with Exact Sciences Corporation, a significant competitor in the arena of colorectal cancer screening. This resolution comes after a series of favorable outcomes for Geneoscopy at the Patent Trial and Appeal Board (PTAB), which has bolstered the company's confidence in its flagship product, ColoSense.

The Legal Background


The culmination of years of legal disputes, this settlement—including the dismissal of all claims in the U.S. District Court for the District of Delaware—marks a significant turning point for Geneoscopy. Both companies have agreed to these terms without acknowledging any liability or wrongdoing. This development allows Geneoscopy to place greater emphasis on its groundbreaking technologies and to expand the reach of its diagnostic tools without the cloud of litigation hanging over its head.

Initially, Geneoscopy took aim at the claims made by Exact Sciences, which included allegations surrounding patent infringements and misleading advertising. However, Geneoscopy's string of victories at the PTAB finished with a clean slate for the company: all contested patent claims asserted by Exact Sciences were deemed unpatentable. In mid-2025, the Patent Office made crucial findings, concluding that the 20 claims of Exact Sciences' U.S. Patent No. 11,634,781 were obvious and thus invalid. This pivotal ruling motivated Exact Sciences to withdraw its efforts to restrict ColoSense from reaching the market, ultimately leading to this recent settlement.

Focus on ColoSense and Future Goals


The resolution of these legal challenges is especially significant for Geneoscopy as it allows the company to concentrate on expanding the availability and innovation of its flagship colorectal cancer screening tool, ColoSense. Developed to detect specific RNA markers related to colorectal neoplasia through a noninvasive stool test, ColoSense represents a major advancement in gastrointestinal health diagnostics. It is designed not only for average-risk adults aged 45 and over but is also touted as an essential option in the American Cancer Society's colorectal screening guidelines.

Andrew Barnell, co-founder and CEO of Geneoscopy, expressed his excitement about the outcome. He stressed the importance of innovation in medical science and emphasized that the legal challenges were distractions from Geneoscopy's mission to enhance patient care through cutting-edge technology. “With the termination of litigation that never should have been brought and the PTAB's invalidation of patents that never should have issued, we can now shift our focus to where it belongs—putting ColoSense within reach of every eligible patient,” Barnell stated.

Implications for Future Collaborations and Developments


In light of this settlement, Geneoscopy is not only focused on promoting ColoSense but also looks ahead to developing a broader pipeline of RNA-based tests for various gastrointestinal conditions, including inflammatory bowel disease. The successful navigation of these legal waters positions Geneoscopy well within the competitive landscape of healthcare diagnostics, as it aims to leverage its proprietary RNA biomarker platform further.

Patients across the United States can now access ColoSense through various healthcare providers. This development promises both greater convenience and enhanced detection methods for colorectal health—a crucial area in healthcare that has historically needed innovative solutions.

Overall, the settlement with Exact Sciences signifies a new chapter for Geneoscopy, opening doors for collaboration and growth while reaffirming its commitment to advancing gastrointestinal health diagnostics. As the company embraces its future endeavors, its focus remains on innovation, patient accessibility, and ongoing development of vital healthcare tools. For more information on Geneoscopy and its offerings, visit geneoscopy.com or learn more about ColoSense at colosense.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.